Comparative effectiveness of probiotic strains for the treatment of pediatric atopic dermatitis: A systematic review and network meta-analysis.

Autor: Tan-Lim CSC; Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines., Esteban-Ipac NAR; Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines., Mantaring JBV 3rd; Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines., Chan Shih Yen E; Singapore Clinical Research Institute, Singapore City, Singapore., Recto MST; Section of Allergy and Immunology, Department of Pediatrics, Philippine General Hospital, Manila, Philippines., Sison OT; Institute of Clinical Epidemiology, National Institutes of Health, University of the Philippines Manila, Manila, Philippines., Alejandria MM; Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines.
Jazyk: angličtina
Zdroj: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology [Pediatr Allergy Immunol] 2021 Jan; Vol. 32 (1), pp. 124-136. Date of Electronic Publication: 2020 Jul 05.
DOI: 10.1111/pai.13305
Abstrakt: Background: The current evidence on the use of probiotics in treating atopic dermatitis is inconclusive. This study determined the comparative effectiveness of the different types of probiotic strains in treating pediatric atopic dermatitis.
Methodology: Systematic and manual search for all randomized controlled trials available from inception until January 31, 2020, was done. Two independent authors conducted the search, screening, appraisal, and data abstraction. Network meta-analysis was conducted using STATA 14 software.
Results: Twenty-two studies involving 28 different probiotic strains were included. The top three ranked probiotic strains in terms of efficacy are Mix1 (Bifidobacterium animalis subsp lactis CECT 8145, Bifidobacterium longum CECT 7347, and Lactobacillus casei CECT 9104); Lactobacillus casei DN-114001; and Mix6 (Bifidobacterium bifidum, Lactobacillus acidophilus, Lactobacillus casei, and Lactobacillus salivarius). Compared with placebo, Mix1 reduces atopic dermatitis symptoms with high certainty evidence (SMD -1.94, 95% CI -2.65 to -1.24; 47 participants). Mix6 compared with placebo probably reduces atopic dermatitis symptoms based on moderate certainty evidence (SMD -0.85, 95% CI -1.50 to -0.20; 40 participants). Lactobacillus casei DN-114001 compared with placebo may reduce atopic dermatitis symptoms based on low certainty evidence (SMD -1.35, 95% CI -2.04 to -0.65). In terms of safety, the highest ranked strain is Lactobacillus fermentum VRI-003, while the lowest ranked strain is Lactobacillus rhamnosus GG.
Conclusion: Certain probiotic preparations show benefit in reducing allergic symptoms in pediatric atopic dermatitis.
(© 2020 EAACI and John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: